Chappellet Becomes the Only American Winery to Be Named a Relais & Châteaux Preferred Partner
7.2.2023 17:00:00 EET | Business Wire | Press release
Napa Valley’s acclaimed Chappellet winery ( www.chappellet.com ) is excited to announce that it has been invited to become a Relais & Châteaux Preferred Partner. With this honor, Chappellet becomes the first American winery to be invited to become a Preferred Partner and joins an exclusive list of some of the world’s top wineries to be named a Relais & Châteaux Partner. Established in 1954, Relais & Châteaux is an association of more than 580 hotels and restaurants around the world operated by independent innkeepers, chefs, and owners who share a passion for excellence and a desire for authenticity in their relationships with their clientele. Preferred Partners are selected based on their shared values with Relais & Châteaux and their ability to provide unique and unforgettable experiences in their signature areas of expertise. “As a multigeneration, family-owned-and-operated winery that shares Relais & Châteaux's values and passion for excellence, we are thrilled to build on our longstanding relationship with Relais & Châteaux as a Preferred Partner,” said Cyril Chappellet, the second-generation president and chairman of Chappellet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230207005010/en/
View of Chappellet’s renowned estate vineyard on Pritchard Hill. (Photo: Business Wire)
Founded in 1967 by legendary vintners Donn and Molly Chappellet, Chappellet was the second post-Prohibition winery established in the Napa Valley. Inspired by the notion that “Bacchus loves the hills,” the Chappellet family settled on Pritchard Hill in the eastern mountains of Napa Valley, where they became some of the earliest pioneers of high-elevation vineyard planting. Though grapes grown above 1,000 feet represent only approximately 3% of total production in California, mountain-grown wines represent a significant portion of the most iconic and sought-after wines in America. Still independent and family-run today, Chappellet’s mountain-grown Cabernet Sauvignons from Pritchard Hill have earned global renown and are recognized as benchmarks for their region, having received multiple 100-point scores and glowing comparisons to the First Growths of Bordeaux from top wine critics.
“Since 1967, our family’s winery on Pritchard Hill has been dedicated to crafting world-class, mountain-grown Cabernet Sauvignon,” added Cyril Chappellet. “Like each Relais & Châteaux property, we strive for perfection in everything we do, from the meticulous way we organically farm our vineyard to the deep and enduring bonds we forge with our customers. Over the years, we have enjoyed remarkable relationships with many Relais & Châteaux owners and properties in North America. We look forward to building on these strong connections as we grow our presence around the globe.”
Chappellet has been partnering with a number of Relais & Châteaux properties in North America over the past decade, hosting curated weekends for their collectors at prestigious properties that include Triple Creek Ranch in Montana, The Wauwinet in Nantucket, Massachusetts, Planters Inn in Charleston, South Carolina and Auberge du Soleil in Napa Valley, California.
“I have had the pleasure of working with Chappellet at multiple Relais & Châteaux properties for the last 15 years,” said Molly Smith, the general manager of Triple Creek Ranch. “The history, familiarity, and elegance that the winery has carried through to the guests has elevated experiences and memories.”
As a Preferred Partner, Chappellet will be hosting additional special “Collectors’ Weekends” for both Relais & Châteaux members and Chappellet collectors at Relais & Châteaux properties throughout North America in 2023. The winery will also be developing new ways to engage with Relais & Châteaux members and its global association of restaurants and hotels, including vintner dinners, tasting events, wine education experiences, and the expansion of Chappellet’s “Collectors’ Weekends” into Europe and Asia.
In commenting on Chappellet’s new status as a Preferred Partner, David Fink, the proprietor of Relais & Châteaux property L'Auberge Carmel, said, “More than half a century ago, Donn Chappellet left his corporate life in Los Angeles to find one of the most idyllic places to raise a family and become a wine grower. Today, the Chappellet family carries Donn's vision forward and has created some of the most special wines made in California.”
About Chappellet
In 1967, on the advice of legendary winemaker André Tchelistcheff, the Chappellet family settled on the steep slopes of Pritchard Hill© and founded Chappellet, becoming just the second post-Prohibition winery in Napa Valley. As pioneers of high-elevation vineyard planting, Chappellet has earned acclaim for crafting benchmark wines with an emphasis on mountain-grown Cabernet Sauvignons, while establishing Pritchard Hill as one of the world’s great wine regions.
About Relais & Châteaux - A Movement with Meaning
Relais & Châteaux, established in 1954, is an association of 580 unique hotels and restaurants throughout the world, owned and operated by independent entrepreneurs – most often families – who are passionate about their craft and deeply committed to forging warm, lasting relationships with their guests. Relais & Châteaux members protect and promote the wealth and diversity of the world’s culinary and hospitality traditions, to ensure they continue to thrive. They are equally dedicated to preserving local heritage and the environment, as articulated in the association’s Vision presented to UNESCO in November 2014. For more information, visit www.relaischateaux.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005010/en/
Contact information
Sonia Ginsburg
Sonia@jam-pr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
